

13. Melamed ML, Michos ED, Post W *et al.* (2008) 25-Hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med* **168**, 1629–1637.
14. Michaelsson K, Baron JA, Snellman G *et al.* (2010) Plasma vitamin D and mortality in older men: a community-based prospective cohort study. *Am J Clin Nutr* **92**, 841–848.
15. Steingrimsdottir L, Gunnarsson O, Indridason OS *et al.* (2005) Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. *JAMA* **294**, 2336–2341.
16. Canadian Cancer Society (2007) Canadian Cancer Society Announces Vitamin D Recommendation. [http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2007/Canadian%20Cancer%20Society%2020Announces%20Vitamin%20D%20Recommendation.aspx?sc\\_lang=en](http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2007/Canadian%20Cancer%20Society%2020Announces%20Vitamin%20D%20Recommendation.aspx?sc_lang=en)
17. International Agency for Research on Cancer (2008) *Vitamin D and Cancer. IARC Working Group Reports* no. 5. Lyon: IARC; available at [http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report\\_VitD.pdf](http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf)
18. Sanders KM, Stuart AL, Williamson EJ *et al.* (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* **303**, 1815–1822.
19. Grant WB, Schwalfenberg GK, Genus SJ *et al.* (2010) An estimate of the economic burden and premature deaths due to vitamin D deficiency in Canada. *Mol Nutr Food Res* **54**, 1172–1181.
20. Grant WB, Garland CF & Holick MF (2005) Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. *Photochem Photobiol* **81**, 1276–1286.

### Vitamin D

#### The vitamin D requirement during human lactation: the facts and IOM's 'utter' failure

Madam

The new Institute of Medicine (IOM) recommendation for vitamin D intake is stated to be 10 and 10–15  $\mu\text{g}/\text{d}$  for the newborn infant and lactating mother, respectively<sup>(1)</sup>, and represents only a marginal change from its previous recommendations<sup>(2)</sup>. We have no issue with respect to the infant recommendations; however, the lactating woman's recommendation is another matter. Our lab has been investigating this area for more than three decades and was the first to actually quantify the vitamin D compounds in human milk<sup>(3)</sup>. Surprisingly, most of our data have been ignored in favour of the original recommendation – or, more appropriately, 'the estimation' – by Blumberg, Forbes and Fraser in 1963<sup>(4)</sup>.

As a graduate student in human nutrition in the 1970s (B.W.H.), the senior investigator in our lab Dr Hollis was struck by the teaching that human milk was the 'perfect' food for the human neonate with one exception: it was inadequate with respect to vitamin D content, and rickets could result in the nursing infant if not provided with exogenous vitamin D supplementation. How could this be? What did these infants do prior to the discovery of vitamin D and how could nature have allowed this to happen? Actually, the answer is quite simple: we in

medicine believed our own dogma instead of actually following the science, and thus we tried to 'fit' our 10  $\mu\text{g}/\text{d}$  recommendation to the physiology instead of applying the physiology to discover the true recommendation.

First, it was said that milk had plenty of vitamin D due to the presence of vitamin D-sulfate. In fact, research 'conveniently' demonstrated that vitamin D-sulfate provided activity of about 10  $\mu\text{g}/\text{d}$  in human milk<sup>(5)</sup>. The problem was that this research was faulty: vitamin D-sulfate did not exist in milk at all<sup>(6)</sup>, so we were back to the drawing board. Accurate assessment had shown the vitamin D content of human milk in 'normal' lactating women to be less than 2.5  $\mu\text{g}/\text{l}$ <sup>(3,7)</sup>. We had shown that lactating women exposed to UV light or given high oral doses of vitamin D to control hypoparathyroidism could produce milk that contained extremely high levels of antirachitic activity of up to 200  $\mu\text{g}/\text{l}$ <sup>(8,9)</sup>. This increase in activity was almost totally due to the parent compound, vitamin D, gaining access to the milk and not the major circulating form, 25-hydroxyvitamin D (25(OH)D)<sup>(8,9)</sup>. But, how could this knowledge be applied to 'normal' women since it was 'well known' that intakes of vitamin D in excess of 50  $\mu\text{g}/\text{d}$  would result in toxicity?<sup>(2)</sup> Because of this belief, this area of research lay dormant for nearly two decades; our laboratory being as guilty as anyone else's for believing it. Fortunately, our view on this matter changed when Vieth *et al.*<sup>(10)</sup> published a seminal paper in 2001 that demonstrated oral intakes of vitamin D<sub>2</sub> up to 100  $\mu\text{g}/\text{d}$  were safe.

Let us piece together the physiology for vitamin D metabolism in the human female. The parent compound, vitamin D<sub>3</sub>, is mostly derived from human skin following exposure to UV light, which can result in the release of several thousand IU/d into the circulation<sup>(11)</sup>. This vitamin D<sub>3</sub> is 'loosely' bound to the vitamin D-binding protein (DBP) with a circulating half-life of approximately 1 d<sup>(12)</sup>. A portion of this parent compound is metabolized to 25(OH)D, which is 'tightly' bound to the DBP with a circulating half-life of approximately 3 weeks<sup>(12)</sup>. Here is where one has to pay attention to the physiology. While 25(OH)D is the major circulating form of vitamin D, it is poorly transferred into human milk while the parent vitamin D is readily transferred<sup>(8,9,13)</sup>. The problem is that because the half-life of vitamin D is so fast, it has to be replenished daily to be effective and this replenishment has to be substantially greater than the 'artificial' requirement of 10  $\mu\text{g}/\text{d}$ , which does nothing to raise the circulating parent vitamin D<sub>3</sub> levels in the mother. In fact, one can use all this data and simply calculate that for each 25  $\mu\text{g}$  intake of vitamin D by the mother daily she will deposit approximately 2.5  $\mu\text{g}$  of antirachitic activity into a litre of her milk. Thus, one can supplement the lactating women with vitamin D at 150  $\mu\text{g}/\text{d}$  or let her obtain significant sun exposure and she will not only replete herself but also supply her nursing infant with vitamin D in her milk at 12.5  $\mu\text{g}/\text{l}$  or so. The sun exposure part does not

currently fit into our culture but it was how vitamin D was obtained for untold thousands of years before we became civilized and warned that sunlight was a carcinogen to be avoided.

Clinically, this fact has been clearly demonstrated in a recent publication from our group that effectively raised the antirachitic activity of human milk to a level that sustains the nursing infant with no harm to the mother<sup>(14)</sup>. Subsequently we received a large grant from the National Institutes of Health to study this approach further, in which we give mothers 50 or 150 µg vitamin D<sub>3</sub>/d compared with controls receiving 10 µg vitamin D<sub>3</sub>/d (and concomitant vitamin D<sub>3</sub> drops of 0IU to the infants of mothers in the high-dose groups and 10 µg/d to the infants whose mothers are receiving 10 µg/d) to sustain not only maternal circulating levels of vitamin D and 25(OH)D, but also her nursing infant's. The 5-year project is nearing completion and we have not encountered a single adverse event related to high-dose maternal vitamin D supplementation. It should be noted, however, that we had to terminate the 50 µg/d arm of the trial because through our DSMC it was determined that this dose was 'inadequate' at supplying the nursing infant with sufficient amounts of vitamin D to maintain normal infant total circulating 25(OH)D level. Why, because a 5 µg/d intake even for a neonate is not an adequate amount. Just think, only a few years ago, that 50 µg/d dose was thought to cause vitamin D toxicity. Isn't science a wonderful force if one actually pays attention and follows the data?

Bruce W. Hollis, Carol L. Wagner

Division of Neonatology, Department of Pediatrics  
Medical University of South Carolina  
173 Ashley Avenue, MSC 513, Charleston  
SC 29425, USA

Email: hollisb@musc.edu

doi: 10.1017/S1368980011000309

### References

1. Institute of Medicine (2011) *Dietary Reference Intakes for Vitamin D and Calcium*. Washington, DC: National Academies Press.
2. Food and Nutrition Board, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes (1997) *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. Washington, DC: National Academies Press.
3. Hollis B, Roos B & Lambert P (1981) Vitamin D and its metabolites in human and bovine milk. *J Nutr* **111**, 1240–1248.
4. Blumberg R, Forbes G & Fraser D (1963) The prophylactic requirement and the toxicity of vitamin D. *Pediatrics* **31**, 512–525.
5. Lakdawala DR & Widdowson EM (1977) Vitamin D in human milk. *Lancet* **1**, 167–168.
6. Hollis B, Roos B, Drapper H *et al.* (1981) Occurrence of vitamin D sulfate in human milk whey. *J Nutr* **111**, 384–390.

7. Hollis BW (1983) Individual quantitation of vitamin D<sub>2</sub>, vitamin D<sub>3</sub>, 25(OH)D<sub>2</sub> and 25(OH)D<sub>3</sub> in human milk. *Anal Biochem* **131**, 211–219.
8. Greer FR, Hollis BW, Cripps DJ *et al.* (1984) Effects of maternal ultraviolet B irradiation on vitamin D content of human milk. *J Pediatr* **105**, 431–433.
9. Greer FR, Hollis BW & Napoli JL (1984) High concentrations of vitamin D<sub>2</sub> in human milk associated with pharmacologic doses of vitamin D<sub>2</sub>. *J Pediatr* **105**, 61–64.
10. Vieth R, Chan PC & MacFarlane GD (2001) Efficacy and safety of vitamin D<sub>3</sub> intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr* **73**, 288–294.
11. Matsuoka LY, Wortsman J, Haddad JG *et al.* (1989) *In vivo* threshold for cutaneous synthesis of vitamin D<sub>3</sub>. *J Lab Clin Med* **114**, 301–305.
12. Haddad JG, Matsuoka LY, Hollis BW *et al.* (1993) Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* **91**, 2552–2555.
13. Hollis BW, Pittard WB & Reinhardt TA (1986) Relationships among vitamin D, 25(OH)D, and vitamin D-binding protein concentrations in the plasma and milk of human subjects. *J Clin Endocrinol Metab* **62**, 41–44.
14. Wagner C, Hulsey T, Fanning D *et al.* (2006) High dose vitamin D<sub>3</sub> supplementation in a cohort of breastfeeding mothers and their infants: a six-month follow-up pilot study. *Breastfeed Med* **2**, 59–70.

### Vitamin D

#### Finding the appropriate referent for vitamin D

Madam

Organisms, as they evolve, come into an exquisite equilibrium with their environment. Those that inhabit starved environments depend upon them mainly as a source of water, energy and minerals. The vast array of organic molecules they need for metabolism they make for themselves. From the standpoint of energy that is expensive, and such organisms tend to be – and to remain – relatively simple. When the environment itself provides many of the compounds necessary for metabolism, organisms tend to shed the biochemical apparatus for making them for themselves. For man, examples are the essential amino acids, essential fatty acids and the array of compounds we call 'vitamins'.

It was not until World War II, when governments began to be concerned about ensuring optimal fighting status of their military, that the first nutrient intake recommendations were developed. For the most part, it seems that governments took as their starting point the prevailing intakes of populations that did not have the then-recognized explicit nutrient deficiency diseases. This is clearly the approach the Institute of Medicine (IOM) used in its recently released recommendations for calcium and vitamin D<sup>(1)</sup>. This stratagem is not altogether unreasonable if one's main concern is to ensure that beriberi and pellagra (for example) are not impairing the health of the population. By that criterion the diets of groups free of these disorders are, obviously, adequate. However, this approach makes no provision for